Connect with us

Business

Denali slips as a snapshot of early data raises some troubling questions on its pioneering blood-brain barrier neuro work – Endpoints News

Denali Therapeutics had drummed up considerable hype for their blood-brain barrier technology since launching over six years…

Published

on

Article feature image
ADVERTISEMENT

Biosimilars have proven time and again (although mostly in Europe) that competition works to bring down the cost of a once-pricey biologic, and can even expand its use.
J&J’s Remicade, however, has always proven to be an outlier.
Back in 2016, Pfizer won…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Chinese cities seize Evergrande presales to block potential misuse of funds – Financial Times
Article feature image
Behave normally, UK transport minister tells Britons queuing for fuel – Reuters
How a California distillery is turning fire-damaged grapes into ‘something awesome’ – The Guardian